509143-03-7

Basic information

• Product Name: cis-(4-tert-butoxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester
• Synonyms: cis-(4-tert-butoxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester
• CAS NO: 509143-03-7
• Molecular Weight: 348.442
• Mol File: 509143-03-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: cis-(4-tert-butoxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: cis-(4-tert-butoxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester(509143-03-7)
• EPA Substance Registry System: cis-(4-tert-butoxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester(509143-03-7)

Safety Data

• Hazardous Substances Data: 509143-03-7(Hazardous Substances Data)

Upstream product

• 247570-24-7 tert-butyl N-[(1s,4s)-4-aminocyclohexyl]carbamate 
• 501-53-1 benzyl chloroformate 
• 53292-90-3 cis-4-tert-butoxycarbonylaminocyclohexane-1-ylcarboxylic acid 
• 100-51-6 benzyl alcohol 
• 3685-23-2 cis-4-aminocyclohexane-1-carboxylic acid 
• 149423-70-1 (±)-cis-N1-benzyloxycarbonyl-1,4-cyclohexanediamine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 247570-24-7 tert-butyl N-[(1s,4s)-4-aminocyclohexyl]carbamate 
• 1439908-80-1 C₁₈H₂₇ClN₄O₄ 
• 1439908-81-2 C₁₆H₂₃ClN₄O₄ 
• 1439908-82-3 C₂₂H₂₈N₈O₄ 
• 1439907-37-5 4-(4-aminocyclohexylamino)-2-(phenylamino)pyrimidin-5-carboxamide 
• 1025061-37-3 cis-[4-(2-methoxy-5-pyridin-4-yl-benzylamino)-cyclohexyl]-carbamic acid tert-butyl ester 
• 149423-70-1 (±)-cis-N1-benzyloxycarbonyl-1,4-cyclohexanediamine 

Relevant articles and documents

SELECTIVE KINASE INHIBITORS

Provided are pyrimidine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

QUINOLINE, TETRAHYDROQUINOLINE AND PYRIMIDINE DERIVATIVES AS MCH ANTAGONIST

The present invention relates to compounds of the Formula (I) wherein Q is: which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.